AXDX:NSD-Accelerate Diagnostics Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 0.59

Change

-0.01 (-2.27)%

Market Cap

USD 0.04B

Volume

1.27M

Avg Analyst Target

USD 5.00 (+752.51%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Accelerate Diagnostics Inc (AXDX) Stock Analysis:
Based on the Accelerate Diagnostics Inc stock forecasts from 2 analysts, the average analyst target price for Accelerate Diagnostics Inc is USD 5.00 over the next 12 months. Accelerate Diagnostics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Accelerate Diagnostics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Accelerate Diagnostics Inc’s stock price was USD 0.59. Accelerate Diagnostics Inc’s stock price has changed by -18.18% over the past week, -40.67% over the past month and -91.74% over the last year.

About

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and anti ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-23.67 (-7.13%)

USD32.59B 169.82 82.97
ALGN Align Technology Inc

-11.48 (-4.09%)

USD22.11B 31.59 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

-10.00 (-5.00%)

USD13.87B 833.46 89.19
ABMD Abiomed Inc

-17.77 (-6.88%)

USD11.76B 86.65 42.14
BRKR Bruker Corporation

-1.19 (-1.94%)

USD9.14B 33.83 17.75
SWAV ShockWave Medical Inc

-3.12 (-1.89%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

-2.54 (-4.08%)

USD5.18B 33.86 18.04
TNDM Tandem Diabetes Care Inc

-3.17 (-4.24%)

USD4.78B 311.29 199.02
IRTC iRhythm Technologies Inc

-7.53 (-5.66%)

USD3.99B N/A N/A

ETFs Containing AXDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -88.76% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.76% 1% F 1% F
Trailing 12 Months  
Capital Gain -91.73% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.73% 3% F 2% F
Trailing 5 Years  
Capital Gain -97.89% 8% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.89% 8% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -29.59% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.59% 7% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 27.13% 86% B 59% F
Risk Adjusted Return -109.05% 3% F 1% F
Market Capitalization 0.04B 26% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -0.88 41% F 55% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -91.45% 11% F 12% F
Return on Assets -50.69% 10% F 5% F
Debt to Equity Ratio -307.90% 98% A+ 96% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.46 13% F 9% F
Short Percent 16.16% 6% F 10% F
Beta 1.80 18% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.